Pharvaris
David Nassif is a seasoned executive with extensive experience in finance and leadership roles across the biotechnology and pharmaceutical sectors. Currently serving as CFO/CLO at Pharvaris since April 2024, David has held key positions including Chief Executive Officer at Sio Gene Therapies Inc. from January 2022 to February 2023, and previously as Chief Financial Officer and General Counsel at Sio Gene Therapies from July 2019 to January 2022. Other notable roles include Executive Vice President and Chief Financial Officer at SteadyMed Ltd and President and CFO at Histogen, Inc. David holds a J.D. from the University of Virginia School of Law and a B.Sc. in Commerce from the University of Virginia.
This person is not in any teams
This person is not in any offices
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.